The importance of histologic type on breast cancer survival

Journal of Clinical Epidemiology

Volumn 50, Issue 3, 1997, Pages 283-290

  Northridge, Mary E ^a   Rhoads, George G ^a   Wartenberg, Daniel ^a   Koffman, Dawn ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Breast neoplasms; Epidemiology; Histologic type; Infiltrating duct carcinoma; Mucinous adenocarcinoma; Survival analysis

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CAUSE OF DEATH; FEMALE; HISTOLOGY; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOFIBROMA; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LIFE TABLES; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 0030951481     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(96)00366-6     Document Type: Article

References (14)

1. Holt JT, Jensen RA, Page DL. Histopathology: Old principles and new methods. Cancer Surveys 1993; 18: 115-133.
2. Ellis IO, Galea M, Broughton N, Locker A, Blarney RW, Elston CW. Pathologic prognostic factors in breast cancer. II. Histologic type. Relationship with survival in a large study with long-term followup. Histopathology 1992; 20: 479-489.
3. Melamed MR, Robbins GF, Foote FW. Prognostic significance of gelatinous mammary carcinoma. Cancer 1961; 14: 699-704.
4. Norris HJ, Taylor HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. Cancer 1965; 18: 879-885.
5. Statistical Analysis System (SAS) Institute Inc. SAS/STAT User's Guide. Release 6.03 Edition. Cary, NC: SAS Institute Inc., 1988.
6. Kelsey JL, Thompson WD, Evans AS. Methods in Observational Epidemiology. New York, NY: Oxford University Press; 1986.
7. Stalsberg H, Thomas DB. Age distribution of histologic types of breast carcinoma. Int J Cancer, 1993; 54: 1-7.
8. Silverberg SG, Kay S, Chitale AR, Levitt SH. Colloid carcinoma of the breast. Am J Clin Pathol 1971; 55: 355-363.
9. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
10. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992; 326: 1756-1761.
11. Fisher ER, Anderson S, Redmond C, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. Cancer 1993; 71: 2507-2514.
12. Fisher ER, Redmond C, Fisher B, et al. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Nat Cancer Inst Monographs 1992; 11: 151-157.
13. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-110.
14. Evans RA. Letter to the Editor. N Engl J Med 1992; 327: 317-318.